Publikation

Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy

Wissenschaftlicher Artikel/Review - 23.12.2012

Bereiche
PubMed
DOI

Zitation
Neidert M, Dietrich P, Herold-Mende C, Rammensee H, Honegger J, Melms A, Christ L, Trautwein N, Trautwein C, Schoor O, Stevanovic S. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. J Neurooncol 2012; 111:285-94.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
J Neurooncol 2012; 111
Veröffentlichungsdatum
23.12.2012
eISSN (Online)
1573-7373
Seiten
285-94
Kurzbeschreibung/Zielsetzung

Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutical strategies have great potential, but the reported repertoire of tumor associated antigens is only for HLA-A 02 positive tumors. We describe the first analysis of HLA-peptide presentation patterns in HLA-A 02 negative glioma tissue combined with gene expression profiling of the tumor samples by oligonucleotide microarrays. We identified numerous candidate peptides for immunotherapy. These are peptides derived from proteins with a well-described role in glioma tumor biology and suitable gene expression profiles such as PTPRZ1, EGFR, SEC61G and TNC. Information obtained from complementary analyses of HLA-A 02 negative tumors not only contributes to the discovery of novel shared glioma antigens, but most importantly provides the opportunity to tailor a patient-individual cocktail of tumor-associated peptides for a personalized, targeted immunotherapeutic approach in HLA-A 02 negative patients.